Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) slow stomach emptying, reduce appetite, and can keep changing weight before and after plastic surgery. October 2024 guidance from several medical societies, including the American Society of Anesthesiologists, says many patients can continue these medicines before elective surgery. A separate 2025 consensus suggests a longer fast from solid food. The two documents do not say the same thing. Your surgeon, anesthesiologist and the clinician who prescribes the medicine decide. The American Society of Anesthesiologists' October 2024 news release says about one in eight U.S. adults use a GLP-1 medicine.
This page is general information, not medical advice. It does not tell you to stop, skip or restart a dose. Follow the written plan from your surgeon, your anesthesiologist and the clinician who prescribes the medicine.
Do I have to tell my surgeon and anesthesiologist?
Yes. Put the medicine on the list you give both of them, and tell the clinician who prescribes it that you have a surgery date. Name the product, the dose, how often you take it, when you started, and whether the dose is still going up. Include a compounded product, a med-spa injection, and a pill or drop marketed as the same drug. Patients sometimes leave these off because they do not think of them as prescriptions.
FDA labels for Wegovy (semaglutide) and Mounjaro (tirzepatide) say there have been rare reports of stomach contents entering the lungs in people taking a GLP-1 receptor agonist who had elective surgery or a procedure under general anesthesia or deep sedation, even when they reported following usual fasting instructions. Both labels say the available data are not enough to show whether changing the fast, or stopping the medicine for a while, would lower that risk, and both say to tell health care providers before any planned surgery or procedure. Tirzepatide, the ingredient in Mounjaro and Zepbound, also activates a second hormone receptor (GIP). The 2024 multi-society document says its suggestions may be applied to current medicines that contain a GLP-1 receptor agonist, and that future drugs may need a new look.
A January 2024 review in Plastic and Reconstructive Surgery—Global Open says surgeons should ask, because people often do not volunteer a medicine they think of as optional. Pre-op timeline · Labs and medical clearance
Do I have to hold a dose before anesthesia?
There is no single answer on this page, and there is not one in the published guidance either. Plans vary. The surgical team decides.
In June 2023 the American Society of Anesthesiologists suggested holding a daily GLP-1 medicine on the day of an elective procedure and holding a weekly medicine for a week, for adults and children, whatever the reason for the prescription. On October 29, 2024, a multi-society document that includes the ASA moved away from a hold as the default. It was published in Clinical Gastroenterology and Hepatology and says it is guidance, not an evidence-based guideline. The societies are the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the ASA, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons.
That 2024 document says use of the medicine around a procedure should be a shared decision among you, the procedural team, anesthesia, and the prescribing clinician. It says therapy may be continued before the procedure when there is not an elevated risk of delayed stomach emptying and aspiration. It lists factors that raise that risk: still being in the dose-increase phase rather than a steady dose; a higher dose; a weekly medicine rather than a daily one; gastrointestinal symptoms such as nausea, vomiting, abdominal pain, indigestion or constipation; and other conditions that slow the stomach, including gastroparesis, bowel dysmotility and Parkinson's disease. The ASA news release on the same guidance says the dose-increase phase often lasts four to eight weeks, depending on the medicine and why it was prescribed, and that elective surgery is ideally deferred until that phase has passed and gastrointestinal side effects have eased.
If a team does decide to hold the medicine, the 2024 document says the right length of a hold is not known. It suggests using the 2023 ASA timing in that case: the day of surgery for a daily medicine, and a week before for a weekly medicine. It also says every patient should still be checked on the day of the procedure for symptoms of a slow stomach. Holding the medicine can raise blood sugar in someone who takes it for diabetes, and the document says withholding it only because a person has overweight or obesity should be avoided.
A newer document does not copy those rules. In May 2025 the British Journal of Anaesthesia published a consensus led by the Society for Perioperative Assessment and Quality Improvement, co-sponsored by the American Association of Clinical Endocrinology. For people without significant gastrointestinal symptoms, it recommends continuing the GLP-1 medicine and fasting from solid food for 24 hours, with only clear liquids. It defines significant symptoms as severe nausea, vomiting, or being unable to keep down food or drink, and it says fullness or early fullness alone does not count. For people who do have those significant symptoms, it recommends referral back to the prescribing clinician before an elective procedure that needs anesthesia. It is a consensus statement, not a rule your clinic is required to use.
An earlier plastic-surgery review, from January 2024, suggested considering a stop of injectable GLP-1 medicines at least two weeks before surgery. That suggestion predates the October 2024 multi-society guidance. A March 30, 2026 article on the American Society of Plastic Surgeons site quotes member surgeons who still describe asking some patients to pause a GLP-1 for about two to three weeks before skin-removal surgery. One of them, Katerina Gallus, MD, describes her usual practice as a break of at least two weeks before and two weeks after. Those are individual surgeons' practices in a news article, not the 2024 multi-society document. If you have been told different things, ask which plan your own surgeon, anesthesiologist and prescriber are using, and get it in writing. Medications on the pre-op timeline
Why do these medicines raise aspiration risk?
They delay stomach emptying. Food or liquid can still be in the stomach after a fast that would be enough for someone else. Under general anesthesia or deep sedation, that material can come back up and enter the lungs. The 2024 multi-society document and the FDA labels above describe that risk. The ASA news release says the result can be aspiration pneumonia, which can be fatal.
The same 2024 document says teams can lower the risk with a liquid diet before the procedure, a change in the anesthesia plan, or a bedside ultrasound of the stomach when the facility can do one. It says ultrasound is limited by equipment, training and who is allowed to use it. If contents are still a concern on the day, the document says the team and the patient weigh going ahead with extra airway precautions against postponing. None of that is a step to arrange on your own.
What about fasting and a liquid diet?
Usual fasting for healthy adults is a separate ASA topic, summarized on labs and medical clearance. GLP-1 guidance may be stricter for some patients, and the two main documents do not match.
- The 2024 multi-society guidance says a liquid-only diet for at least 24 hours can be used when there is concern for delayed stomach emptying, the way some colonoscopy and bariatric-surgery patients already do. The ASA news release says patients on a higher dose, who more often have gastrointestinal side effects, should follow a liquid diet for 24 hours before the procedure.
- The 2025 SPAQI consensus recommends, for patients without significant gastrointestinal symptoms, no solid food for 24 hours. It also recommends fasting from clear liquids that contain 10% glucose or more for 8 hours, and from clear liquids with less glucose for 4 hours.
Which of those applies to you, or whether your team uses a different protocol, is their decision. Do not invent a fast from a group chat or from this page.
When should weight be stable before a tummy tuck, lipo, BBL, breast lift or skin removal?
Surgeons plan those operations around the fat and skin you have at a given weight. If you are still losing, or likely to regain a large amount, the result is planned for a body you will not still have. That is why they ask for a stretch of stable weight, not a number on the scale the week of surgery.
The American Society of Plastic Surgeons' 2017 practice parameter on skin redundancy says body-contouring surgery is ideally done after weight has been stable for two to six months, and that after bariatric surgery that point often comes 12 to 18 months later. The January 2024 review's recommendation list says to wait at least six months of stable weight before surgery when the loss is from a GLP-1 medicine. The March 2026 ASPS article says many surgeons recommend a stable weight held for at least three to six months, because swings can compromise the result and further loss after surgery may mean another operation. Those intervals are not the same. None of them is a statute. Your surgeon sets the bar for a tummy tuck, liposuction, a BBL, a breast lift or skin removal.
The same review says to talk about using the medicine after surgery, because more weight loss can change the shape, and that some patients may discuss staying on it as a way to limit regain. It also says people who lost weight with these medicines can be treated, after that stable period, like other patients who had a large weight loss, while longer-term differences are still unknown. Skin removal after weight loss · Tummy tuck recovery · Which procedure fits · Breast surgery recovery · How weight change affects a BBL · BMI limits
What can happen during recovery?
FDA labels list nausea, vomiting, diarrhea, abdominal pain and constipation among the most common effects of Ozempic (semaglutide), reported in at least 5% of patients in trials. The Mounjaro (tirzepatide) label lists nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain, also at at least 5%. It says most reports of nausea, vomiting or diarrhea were during dose increases and then eased, and that the delay in stomach emptying is largest after the first dose and lessens over time. Wegovy's label lists a similar set of stomach symptoms. A smaller appetite is the point of the medicine. It can also make it harder to eat enough while an incision is healing.
The January 2024 review says that when portions shrink and protein stays low, patients can lose muscle as well as fat, which the authors connect with poorer wound healing. It suggests a weight-loss clinician individualize protein intake. It does not publish a gram target that applies to every plastic-surgery patient, and this page will not invent one. The March 2026 ASPS article quotes Dr. Gallus on making nutrition, including protein, a priority before and after skin-removal surgery. What to eat, and whether a supplement is appropriate, is a question for your surgeon and the prescribing clinician.
The Mounjaro label says gastrointestinal reactions can lead to dehydration, and that kidney function should be monitored in patients who report reactions that could deplete body fluid, including nausea, vomiting and diarrhea. Tell your team if you cannot keep fluids down. Constipation is on the labels for these medicines. Opioid pain medicine is a separate common cause of constipation after surgery. What to use for that is on post-op medications, and it is still your surgeon's call. Week-by-week recovery · Warning signs
When do patients restart?
Published guidance does not give one restart day after cosmetic surgery. The October 2024 multi-society document is about getting through the procedure safely. It does not set a day to resume for a tummy tuck, lipo, a BBL or a breast operation.
What exists instead is a range of practice. Dr. Gallus, in the March 2026 ASPS article, describes a usual break of at least two weeks before and two weeks after skin-removal surgery so patients can take in nutrition. The January 2024 review says to make a plan, before surgery, for continuing or stopping, with a clinician who manages the medicine. It specifically flags ileus, a slow or stopped bowel, as a concern if the medicine is restarted while opioid pain medicine is still in use. Your surgeon and your prescriber decide whether you restart, at what dose, and when. Do not restart, skip, or change a dose to match a timeline from this page or from another patient.
What happens to results if weight keeps changing?
Fat does not come off one area only, and it does not return to only one area. More loss after a tummy tuck, lipo, breast lift or skin removal can leave looser skin or a shape the operation was not planned for. Regain can fill areas back in, including places that had liposuction. For a BBL, the fat that survives behaves like fat elsewhere, so a large weight change changes the result. That point is on is a BBL worth it.
Stopping the medicine is one way weight comes back. In the STEP 1 trial extension, adults with overweight or obesity and without diabetes took once-weekly semaglutide 2.4 mg, the Wegovy dose, plus a lifestyle program. In the extension group of 327 people, mean weight loss from the start to week 68 was 17.3% with semaglutide. After both the medicine and the lifestyle program were stopped, that group regained 11.6 percentage points by week 120, for a net loss of 5.6%. The paper's conclusion says they regained two-thirds of the prior loss over that year off treatment. The analyses were exploratory, and the result is for that semaglutide dose and that study group. It is not a forecast for tirzepatide, for a lower dose, or for you. The January 2024 review cites this pattern as a reason to discuss regain before body contouring, including the option some patients consider of staying on the medicine to limit it.
What do people mean by Ozempic face or Ozempic body?
They are nicknames, not diagnoses. The January 2024 review uses "Ozempic face," "Ozempic butt" and "Ozempic body" for the deflated look that can follow these medicines. A December 2023 ASPS article quotes member surgeon Kristy Hamilton, MD: when you lose a substantial amount of weight, you lose it in the face as well, and the same change would follow substantial weight loss of any kind, not only Ozempic. In that article, member surgeon Max Polo, MD, describes fillers or a patient's own fat for milder facial volume loss, and a facelift more often when the change is larger. He mentions people who have lost more than 40 or 50 pounds. Those are surgeons describing their practices, not a rule for who needs an operation.
On the body, the March 2026 ASPS article says the faster the loss, the thinner and less resilient the skin may be, and that extra skin can chafe or trap moisture. It lists arm lifts, thigh lifts, lower body lifts, breast lifts and tummy tucks as operations patients ask about after GLP-1 weight loss. Which of those matches your skin, and whether any of them should wait, is a consultation question. The abdominal operations, and how insurance treats them, are on skin removal after weight loss. Confirmed facelift offers are on this week's deals, not a recommendation to have one.
Are compounded GLP-1 products the same as the approved drugs?
No. The FDA says compounded drugs are not FDA-approved. The agency does not review them for safety, effectiveness or quality before they are marketed. A compounded drug might be appropriate when a patient's medical need cannot be met by an approved drug, or when the approved drug is not commercially available. That judgment belongs to a prescriber, not to a website or a med spa.
The FDA says it has received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide. Patients measured and injected the wrong amount, and in some cases clinicians miscalculated the dose. The agency has also received reports that may be related to compounded semaglutide or tirzepatide prescribed in doses, frequencies or dose increases beyond the approved labels, with symptoms that include nausea, vomiting, diarrhea, abdominal pain and constipation. It has warned about fraudulent compounded products whose labels name a pharmacy that did not make them, or a pharmacy that does not exist. The FDA says to use a prescription from your own clinician and a state-licensed pharmacy, and to be wary of sellers that skip a prescription, promise the compounded drug is the same as an approved one, or ship a product that does not match what a pharmacy dispensed before.
Tell your surgeon the exact product, the pharmacy named on it, and the dose, including if it came from a compounding pharmacy or an online clinic. Do not assume a compounded vial is the same drug, dose or schedule as Ozempic, Wegovy, Mounjaro or Zepbound.
General education, not medical advice. Your surgeon, your anesthesiologist and the clinician who prescribes the medicine override this page. In an emergency, call 911.
Sources: ASA news release, multi-society GLP-1 guidance (October 29, 2024); Kindel et al., multi-society guidance, Clinical Gastroenterology and Hepatology, 2024; ASA consensus-based guidance (June 2023); Oprea et al., SPAQI consensus, British Journal of Anaesthesia, 2025; Wegovy (semaglutide) prescribing information, DailyMed; Ozempic (semaglutide) prescribing information, FDA label revised October 2025; Mounjaro (tirzepatide) prescribing information, DailyMed; ASPS practice parameter, surgical treatment of skin redundancy (2017); O'Neill et al., PRS Global Open, January 2024; ASPS, lifts after weight loss (March 30, 2026); ASPS, will you need a facelift after Ozempic (December 5, 2023); Wilding et al., STEP 1 trial extension, Diabetes, Obesity and Metabolism, 2022; FDA, concerns with unapproved GLP-1 drugs used for weight loss.
